Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis

• Published in: Annals of oncology 1995-01, Vol.6 (1), p.65-70
• Main Authors: Enblad, G., Sundström, C., Gronowitz, S., Glimelius, B.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; age; Age Factors; Aged; Aged, 80 and over; Biological and medical sciences; Child; Female; Hematologic and hematopoietic diseases; Hodgkin Disease - blood; Hodgkin Disease - pathology; Hodgkin's disease; Humans; interleukin-2 receptor; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Medicin och hälsovetenskap; Middle Aged; Neoplasm Staging; Orosomucoid - analysis; Prognosis; Receptors, Interleukin-2 - analysis; serum factors; thymidine kinase; Thymidine Kinase - blood
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/oxfordjournals.annonc.a059044

Background The serum levels of soluble interleukin-2 receptor (S-sIL-2R) have been shown to be related to clinical outcome in Hodgkin's disease (HD). sIL-2R may be involved in or aggravate the immunodeficiency seen in HD patients. This immunodeficiency is most pronounced in elderly patients. Patients and methods S-sIL-2R was determined in 127 untreated patients with HD, diagnosed between 1979 and 1991, in order to evaluate its prognostic value in relation to other known prognostic variables with special emphasis on the elderly. Results S-sIL-2R levels were significantly higher in patients with stages IEIV and with B-symptoms (p < 0.001) but not in patients over 60 years of age. In multivariate analyses, S-sIL-2R, stage and S-orosomucoid were the most important prognostic factors in all patients and S-sIL-2R was the only prognostic factor in patients over the age of 60. Conclusions The results indicate a future role for estimation of S-sIL-2R in the management of patients with HD.